Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720
   Google Scholar   
Citation:
J Clin Oncol vol 26 (30) 4934-4939
Meeting Instance:
ASCO 2008
Year:
2008
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
86  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
CA31946, CA33601, )CA31983, CA02599, CA77658, CA35279, CA03927, CA47577, CA32291, CA41287  
Corr. Author:
Baer 
Authors:
                           
Networks:
 
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9720
Phases:
1, 1/2, 2, 3
Keywords: